Panandiker Kaya Kamlesh Pai - 10 Dec 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Reporting relationship: Chief Commercial Officer
Issuer ticker: LBRX on Nasdaq
Reported as of: 10 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Dec 2025, 16:15:13 UTC
Prior SEC filing: 18 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Marc Panoff, Attorney-in-Fact

Key filing fact

Panandiker Kaya Kamlesh Pai filed Form 4 for LB PHARMACEUTICALS INC on 11 Dec 2025.

Key facts

This page summarizes Panandiker Kaya Kamlesh Pai's Form 4 filing for LB PHARMACEUTICALS INC.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Dec 2025, 16:15.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002095250 Primary reporting owner

Pai Panandiker Kaya Kamlesh

Relationship: Chief Commercial Officer
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Marc Panoff, Attorney-in-Fact
Signature date: 11 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +195,000
Change %
Price: $0.000000
Shares after: 195,000
Date: 10 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 195,000
Exercise price: $21.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.